C 014 - Shanghai Pharmaceuticals Holding
Alternative Names: C-014 - Shanghai Pharmaceuticals HoldingLatest Information Update: 12 Feb 2024
At a glance
- Originator Shanghai Pharmaceuticals Holding
- Class Antidementias
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alzheimer's disease
Most Recent Events
- 01 Jan 2024 Phase-I clinical trials in Alzheimer's disease (unspecified route) in China prior to January 2024 (Shanghai Pharmaceuticals Holding pipeline, January 2024)